Discussions
(27 contents)
Discussions
QoL and Functional Measures of Treatment Success
EN
Dr Kosiborod and Dr Zieroth discuss QoL and functional status as tangible measurements of treatment success.
Discussions
Clinical Evidence
EN
Dr Kosiborod and Dr Zieroth look at the relationship between initiating GDMT and QoL / functional status improvement. They discuss some of the specific clinical trial data showing how initiating SGLT-2 inhibitors improves QoL and functional outcomes.
Discussions
Practically Implementing PROMs
EN
In this final part of this series, Dr Kosiborod and Dr Zieroth discuss practical implication of these patient reported outcome measures (PROMs).
Discussions
Initiating SGLT-2 Inhibitors
EN
Prof Rosano and Dr Bozkurt examine recent guidelines and consider best practice for initiating SGLT-2 inhibitors across the continuum of HF and in patients already on HF medication versus those who are treatment-naïve.
Discussions
Evolving the Management Approach - AEs and MDTs
EN
Prof Rosano and Dr Bozkurt discuss the practicalities of continual management of HF patients on an SGLT-2 inhibitor and how the broader multidisciplinary team should be aware of the benefits of early SGLT-2 initiation in HF.
Discussions
What is GDMT?
EN
Prof Coats and Dr Kosiborod summarise foundational guideline-directed medical therapy (GDMT) across the spectrum of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
Discussions
Early Initiation and Better Clinical Outcomes
EN
Prof Coats and Dr Kosiborod discuss the relationship between early initiation of foundational GDMT and better clinical outcomes by exploring recent clinical trial data from STRONG-HF.
Discussions
Achieving Early Uptake of GDMT
EN
In this final part, Prof Coats and Dr Kosiborod cover practical approaches for ensuring early optimal GDMT in heart failure, such as, the use of electronic health records and protocols for specific patient subgroups.
Discussions
The DELIVER Trial in Brief
EN
Prof Lam discusses DELIVER with one of the trial’s lead investigators, Prof McMurray. As well as the key results from DELIVER, they consider how to apply them to HFpEF patients in the real-world.
Discussions
DELIVER and DAPA-HF Pooled Analysis in Brief
EN
Prof Lam and Prof McMurray put into context the pooled analysis of DELIVER and DAPA-HF and consider whether these results can be extrapolated to the entire HF population, addressing the suitability of patients according to their individual EF.
Discussions
Implementation Strategies for GDMT in Respect of the New Guidelines
EN
In this short interview, Dr Kosiborod and Dr Van Spall summarise some of the key changes in guidance following the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Discussions
The PRESERVED-HF Study: Effects of Dapagliflozin
EN
In this short presentation on behalf of the investigators, Dr Kosiborod summarises the PRESERVED-HF study, looking at effects of Dapagliflozin on symptoms and functional status in patients with HF and preserved EF.
Discussions
Effects of Dapagliflozin in Patients With Chronic Kidney Disease
EN
In this presentation of the ESC 2021 poster, 'Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure', Prof McMurray provides a comprehensive overview of the study's background, methods and results.
Discussions
Cardio-renal Pathophysiology
EN
Prof Khunti outlines what clinicians need to know about the relationship between chronic kidney disease and cardiovascular disease. Prof Heerspink addresses why clinicians should be encouraged to intervene early for patients living with CKD.
Discussions
Screening for CKD
EN
Prof Khunti addresses the burden of CKD globally, including the prevalence of CKD in patients with type 2 diabetes. The faculty discuss existing tools for screening for CKD, and the recommendations of international guidelines.
Discussions
Treatment Options in CKD
EN
Dr Zieroth enquires of the latest treatment options for CKD, with Prof Heerspink advising on evidence supporting the use of treatments, whilst Prof Khunti provides insight to the role of initiating SGLT2 therapy, and underlines the urgency to treat.
Discussions
Where Do SGLT-2 Inhibitors Fit Into the New Guidelines for HFrEF?
EN
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano address key considerations of where SGLT-2 inhibitors fit into the new guidelines for HFrEF.
Discussions
When and How to Initiate SGLT-2 Inhibitors in HFrEF
EN
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano provide a comprehensive update on when and how to initiate SGLT-2 inhibitors.
Discussions
Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice
EN
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano discuss how to make evidence-based choices in the selection of SGLT-2 inhibitors.
Discussions
Optimising Treatment of HF
EN
In part one of this programme 'Optimising Treatment of HF', Prof Cowie introduces the topic and reviews the learning objectives.
Discussions
A Review of Recent SGLT2 Inhibitor Data
EN
In part two of 'Optimising Treatment of HF', Prof Rosano reviews recent SGLT2 trial data, including DAPA – HF, and Emperor Reduced.
Discussions
New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?
EN
In part three of 'Optimising Treatment of HF', Dr Butler presents a case, and considers available treatment strategies and the optimal approach for HFrEF medications.
Discussions
Existing HF-REF: Augmenting the SOC
EN
In part four of 'Optimising Treatment of HF', Dr Zieroth reviews how guideline-directed medical therapy for HFrEF has evolved, and notes that further changes are coming to practice.
Discussions
How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?
EN
In the final part of this programme 'Optimising Treatment of HF', Prof Cowie moderates a discussion with the faculty.
Discussions
Guideline Directed Medical Therapy in HF
EN
In this short peer-to-peer discussion, Dr Biykem Bozkurt, and Prof Giuseppe Rosano, discuss the main updates from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Discussions
SGLT-2 Inhibitors Across the Range Of EF
EN
In this short peer-to-peer discussion, Prof Giuseppe Rosano and Dr Mikhail Kosiborod, discuss the main updates from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Discussions
Using Guideline Directed Medical Therapy to Improve Outcomes
EN
In this short peer-to-peer discussion, Prof Giuseppe Rosano and Dr Mikhail Kosiborod, discuss the main updates from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Heart Failure in Focus Podcast
(6 contents)
Podcasts
Episode 6: Cardiorenal Care in Practice
EN
Dr Muthiah Vaduganathan speaks with Dr Kieran McCafferty, Consultant Nephrologist at Barts NHS Health Trust London, about the growing need for effective management strategies in cardiorenal disease.
Podcasts
Episode 5: Functional & QoL Outcomes in a Sea of Clinical Event Data
EN
Dr Vaduganathan is joined by Dr Mikhail Kosiborod, leading expert on Quality of Life (QoL) instruments world-wide, to discuss functional and QoL outcomes of foundational therapies in Heart Failure (HF) and the clinical application of this data.
Podcasts
Episode 4: Mitigating Clinical Inertia in Heart Failure
EN
Dr Vaduganathan is joined by Dr Tariq Ahmad to discuss the reality of sub-optimal treatment and possible ways forward using behavioural “nudges” embedded within electronic health records.
Podcasts
Episode 3: 4 Onboard: Implementing GDMT
EN
Dr Vaduganathan is joined by Dr Biykem Bozkurt, for the third episode, to discuss some of the most challenging questions around implementing guideline directed medical therapy (GDMT).
Podcasts
Episode 2: Your Questions Answered
EN
Dr Vaduganathan is joined by Prof Carolyn Lam to continue the theme of SGLT-2 inhibitors in heart failure. Listen to them answer your questions about SGLT-2 inhibitors and the practical management of heart failure patients.
Podcasts
Episode 1: Emerging Data from the ESC
EN
Dr Muthiah Vaduganathan is joined by Prof Scott Solomon for the first episode in this new series, Heart Failure in Focus, to discuss the DELIVER data which was released at the ESC Congress 2022 in Barcelona.
CME Courses
(2 contents)
CME Courses
Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management
CME Courses
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
Symposia
(7 contents)
Symposia
SGLT2 Inhibitors: Light at the End of the Tunnel
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
Symposia
SGLT2 Inhibitors Across the Spectrum of Heart Failure
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
Symposia
Practical Considerations for Treating HF With Mildly Reduced and Preserved EP
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
Symposia
Implementing Best Practices Across the Spectrum of Heart Failure
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
Symposia
The ACC Heart Failure Guidelines 2022: What Did We Learn?
EN
This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.
Symposia
The Future of Guidelines: Towards Personalised Care?
EN
This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.
Symposia
HFpEF: The Final Chapter in the Heart Failure Story?
EN
This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.
Roundtables
(3 contents)
Roundtables
Ejection Fraction - How Important Is It Today?
EN
During the first part of this roundtable, chaired by Prof Cowie, our multidisciplinary panel discuss the importance of EF, and analyse survey data.
Roundtables
HFrEF and HFpEF Case Review
EN
During the second part of this roundtable, our multidisciplinary panel discuss two patient cases and their treatment strategies based on recent guidelines and data updates.
Roundtables
The Expanding Role of Primary Care in Ongoing HF Management
EN
During the final part of this roundtable, the panel discuss the role of primary care in ongoing heart failure management.